many of these drugs are also approved in other countries, but may have different indications and costs
Across the full GLP-1 and obesity drug space, the post-2026 picture is a price-expansion wave led by Indian and Chinese biosimilars and by new dual or triple-agonist molecules, yet real uptake in the USA and EU will be shaped less by tariffs and more by regulatory timing, drug-device parity on pens and human-factors equivalence for AB-substitution, secondary IP and Orange Book hurdles, and payer or formulary contracting
Wu, Z., Guo, Z., Gearing, M
Caractersticas y beneficios Qu contiene
J.AraiY
The bottom line: a powerful tool, used the right way So who are these drugs for